These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30658046)

  • 1. Development of new agents for peripheral T-cell lymphoma.
    Ito Y; Makita S; Tobinai K
    Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
    Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
    Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
    Broccoli A; Argnani L; Zinzani PL
    Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
    Gisselbrecht C; Sibon D
    Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin in systemic T-cell lymphoma.
    Oki Y; Younes A
    Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belinostat: first global approval.
    Poole RM
    Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
    Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
    Front Immunol; 2022; 13():835103. PubMed ID: 35185926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belinostat for the treatment of peripheral T-cell lymphomas.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.